Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of SY-4835 Tablets in Patients With Advanced Solid Tumor

NCT05291182 is registered in ClinicalTrials.gov with Shouyao Holdings (Beijing) Co. LTD as lead sponsor.

NCT NCT05291182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05291182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of SY-4835 Tablets in Patients With Advanced Solid Tumor
Lead sponsor
Shouyao Holdings (Beijing) Co. LTD
Phase
Phase 1
Overall status
Unknown status
Start date
June 28, 2021
Completion date
December 28, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor